Cargando…

Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?

Osteoporosis is a disease that increases skeletal fracture risk and places a significant health and economic burden on patients, families, and health systems. Many treatment options exist, but patient use is suboptimal, thus undermining the potential cost-effectiveness of treatments. In the previous...

Descripción completa

Detalles Bibliográficos
Autor principal: Laba, Tracey-Lea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060568/
https://www.ncbi.nlm.nih.gov/pubmed/25167089
http://dx.doi.org/10.1186/ar4501
_version_ 1782321391913140224
author Laba, Tracey-Lea
author_facet Laba, Tracey-Lea
author_sort Laba, Tracey-Lea
collection PubMed
description Osteoporosis is a disease that increases skeletal fracture risk and places a significant health and economic burden on patients, families, and health systems. Many treatment options exist, but patient use is suboptimal, thus undermining the potential cost-effectiveness of treatments. In the previous issue of Arthritis Research & Therapy, Hiligsmann and colleagues expanded the findings of previous studies to report, from a sample of 257 patients with osteoporosis, the preference to trade off clinical outcomes for the amenity provided by convenient dosing regimens. This editorial critiques the strengths and limitations of the methods, discusses the potential utility of patient treatment preferences, and suggests avenues for further research.
format Online
Article
Text
id pubmed-4060568
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40605682014-06-17 Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here? Laba, Tracey-Lea Arthritis Res Ther Editorial Osteoporosis is a disease that increases skeletal fracture risk and places a significant health and economic burden on patients, families, and health systems. Many treatment options exist, but patient use is suboptimal, thus undermining the potential cost-effectiveness of treatments. In the previous issue of Arthritis Research & Therapy, Hiligsmann and colleagues expanded the findings of previous studies to report, from a sample of 257 patients with osteoporosis, the preference to trade off clinical outcomes for the amenity provided by convenient dosing regimens. This editorial critiques the strengths and limitations of the methods, discusses the potential utility of patient treatment preferences, and suggests avenues for further research. BioMed Central 2014 2014-03-10 /pmc/articles/PMC4060568/ /pubmed/25167089 http://dx.doi.org/10.1186/ar4501 Text en Copyright © 2014 BioMed Central Ltd.
spellingShingle Editorial
Laba, Tracey-Lea
Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title_full Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title_fullStr Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title_full_unstemmed Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title_short Using Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
title_sort using discrete choice experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060568/
https://www.ncbi.nlm.nih.gov/pubmed/25167089
http://dx.doi.org/10.1186/ar4501
work_keys_str_mv AT labatraceylea usingdiscretechoiceexperimenttoelicitpatientpreferencesforosteoporosisdrugtreatmentswheretofromhere